ROCKVILLE, Md., Dec. 5, 2005 (PRIMEZONE) -- Cytomedix, Inc. (AMEX:GTF), a biotechnology company specializing in the research, development, licensing, and systems for treating non-healing chronic wounds including diabetic ulcers, today announced that The Wall Street Transcript has published an in-depth interview with Chief Executive Officer and Chairman Kshitij Mohan, Ph.D.
The interview is available free on the Cytomedix web site (www.cytomedix.com) or to subscribers at The Wall Street Transcript's web site (www.twst.com).
During the interview, Dr. Mohan noted that Cytomedix addresses a large market for its AutoloGel(tm) System and is licensing its technology to other companies. "The chronic and acute wound market is under-served by the current products that are out there," Dr. Mohan stated. "It's not a question of gaining market share. It's a question of expanding the whole market, which is why our strategy has been to share this with other companies (through licensing agreements). It's a large market for a large unmet clinical need." He added that Cytomedix has a technological answer that it believes will prevail and be competitive with or better than most other products.
Dr. Mohan also expressed cautious optimism regarding the outcome of the ongoing audit of the clinical trial data that the Company is expecting to complete before the end of this year. Patients who were treated strictly according to the protocol will achieve positive results, he concluded.
About Cytomedix
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for uses in the treatment of wounds and other applications. The current offering is the AutoloGel(tm) system, a technology that utilizes an autologous platelet gel composed of multiple growth factors and fibrin matrix. The Company has concluded the treatment phase of a blinded, prospective, multi-center clinical trial on the use of its technology in healing diabetic foot ulcers. Statements in this press release about the future growth of the market or the outcomes of the ongoing audit of the clinical trial results are examples of forward looking statements that may or may not come to fruition. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the success of new sales initiatives, governmental regulation, acceptance by the medical community and competition. Examples of such matters in this press release also include, but are not limited to, discussions regarding the outcome of clinical trial results, FDA's regulatory clearance process or the future coverage of our products by Medicare. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.